RAC - Charts & Price Action, page-242

RO,

COH are already doing an in-man study with Brequinar in AML along with several big US hospitals. Started 2018 and finishing in next 6-12 months.

I think it would be helpful if you reference this when you commentate on what studies COH may or may not do in the future. I wonder why MD Anderson went with Brequinar for their study and not Bisantrene, which would have been available at the time. Was it just logistics or another reason? I suspect it was because RACE was still trying the named patient approach but if you could clarify that would be great.

No reason for COH or the others US groups to do a trial with Bisantrene until the Brequinar study read out as they will just cannibalise their recruitment pool. More preclinical work is a different matter of course.

If you have time do you care to compare and contrast the two candidates from the COH paper? Brequinar is a direct and serious competitor now, particularly for AML.

I don’t think the investors on this site would be able to get the answers to the queries above other than by access to you. Thanks for your time.